📰 Pharm Olam News
Pharm Olam News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharm Olam. Real-time updates on events, politics, business and more.
March 3, 2023
Etrasimod was effective and well tolerated as an induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. Etrasimod is a treatment option with a unique combination of attributes that might address the persistent unmet needs of patients with ulcerative colitis.
February 24, 2022
Cathal Friel to continue in executive chairman role under new management structure
January 19, 2021
Share this article Share this article HOUSTON, Jan. 19, 2021 /PRNewswire/ -- Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial. The JPEO-CBRND awarded Pharm-Olam a $36.3 million agreement to execute an adaptive, outpatie...